Tetratherix (ASX:TTX) said its joint venture partner, Tutelix, completed a Series A funding round from key investors led by a MedTech venture capital firm, bringing the total funds raised by the joint venture to around AU$5 million, allowing the joint venture to fast‑track the prostate spacing clinical trial to move towards an international pivotal study in the Australia and the US, according to a Tuesday Australian bourse filing.

The trial was designed to investigate the ability of the Tutelix spacer to be safely injected between the prostate and rectum to create and maintain space around the prostate.

Around 12 patients included the Tutelix spacer in their treatment, with the space generated by the spacer reducing the radiation dose received by the rectum in each patient. All 12 participants completed or are in the process of completing their radiation treatment plans.

Its shares jumped 5% in recent trading on Tuesday.